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Zollinger-Ellison syndrome (ZES) is a rare disease. Its management concerns
symptoms related to the gastric acid overproduction that characterizes the syn-
drome and to the gastrin-producing tumor(s) usually located in the duodenal
wall and/or the endocrine pancreas. Acid hypersecretion is now controlled by
the use of powerful antisecretory agents. Management of the malignant
process(es) has become the primary goal ofmodern strategy: it aims first at cur-
ing the disease and second at prolonging patient survival by prevention of
hepatic metastasis. In patients with the sporadic form of the disease and with-
out liver metastases, it is currently possible to localize and to surgically remove
the endocrine tumor(s). This progress has been made feasible by refinements in
modern medical imaging. At present, however, disease cure, even in the most
favorable conditions, is not be greater than 30 to 50 percent at five years. In
patients with ZES integrated in the context ofmultiple endocrine neoplasia type
I, disease cure rate is extremely low, although occasional patient survival can be
as good or even better than in the sporadic group. Disseminated malignancy
(liver and/or extra-abdominal lymph nodes or bone localization) remains the
principal determinant of early death. Surgical treatment is usually precluded in
such cases. Liver transplantation has not been successful in these patients.
-~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
INTRODUCTION
The use ofpowerful acid antisecretory agents, first H2 receptor antagonists (H2RAs)e,
then proton pump inhibitors (PPIs), in the last two decades has profoundly facilitated the
management of the Zollinger-Ellison syndrome (ZES). Patients are no longer faced with
the dreadful consequences ofgastric acid overproduction, often treated by total gastrecto-
my, and care is now primarily focused on management ofthe malignant process [1, 2, 3].
Initially, however, management strategies were difficult to assess: patient series were
small, as is the case for rare diseases. Patient follow-up was too short to provide a clear
appreciation ofthe natural history ofthe disease, and medical technology (especially med-
ical imaging) was still in its early stage of development. However, by the late 1980s the
respective roles ofmedical and surgical management of the disease appeared increasing-
ly clear [4, 5, 6]. Medical treatment aimed at controlling acid overproduction and related-
symptoms, at slowing, even in some cases at reducing the patient's chances of a fatal out-
come due to liver metastases (when non-resectable), and eventually at antagonizing the
gastrin-induced overproliferation of gastric fundic enterochromaffin-like (ECL) cells [7,
8]. Surgery aimed at attempting to cure the disease in favorable conditions by tumor
removal and to prevent metachronous liver metastases development [1, 9, 10, 11]. Surgery
sometimes, also aimed at eradication ofECL-omas [10].
aTo whom all correspondence should be addressed: M. Mignon, M.D., Ph.D. Department of
Gastroenterology, Hopital Bichat-Claude Bernard, 75877 Paris, Cedex, France. Tel: 33-1-40-25-72
01; Fax: 33-1-40-25-05-93.
eAbbreviations: GRESZE, Groupe de Recherche et d'IEtude sur le syndrome de Zollinger-Ellison;
ZES, Zollinger-Ellison syndrome; H2RA, H2 receptor antagonist; PPI, proton pump inhibitor; ECL,
enterochromaffin-like; MEN-I, multiple endocrineneoplasia typeI; PCNA, proliferating cell nuclear
antigen; STZ, streptozotocin; 5FU, 5 fluoro-uracil.
289Mignon etal.: Is gastrinoma a medical disease?
It soon appeared, however, that gastrinoma management was more complex than ini-
tially anticipated. Understanding ofthe oncologic process remains incomplete. We are not
able to explain why some patients, even with liver metastases, undergo a relatively indo-
lent course, or why metastases to lymph nodes on the one hand and to liver on the other
hand, although both indicate malignancy, behave differently, only the latter influencing
patient survival.
Indications and contraindications of surgery remained, therefore, highly controversial
with firm opponents to surgery arguing that, except in very rare and selected cases [12],
there is a minute chance of a long-term satisfactory cure rate (15 percent according to
Hirschowitz's experience and a review of 15 series by Ellison et al. [13]). On the contrary,
many other groups, including the NIH group at Bethesda and our group in Paris, on the
basis ofthe results ofearlierexperience, advocated explorative laparotomy in the sporadic
form of the disease, except in patients with diffuse liver metastases. The NIH group
extended this indication even to ZES patients with multiple endocrine neoplasia type I
(MEN-1) [3], provided an imageable tumor was found. We did not adopt this recommen-
dation, as it was not supported by the results of a long-term follow-up of 45 consecutive
patients followed in our institution [14, 15].
Several recent reports on large series ofpatients have provided very significant infor-
mation on two relevant factors: 1) ZES patient survival depends essentially on the pres-
ence of distant metastases, which, in turn, seems to depend upon the size and the local-
ization ofthe primary tumor(s), and 2) disease cure-rate by surgery seems to depend upon
the clinical condition (with or without MEN-1) and the possibility of removal of the pri-
mary tumor as completely as possible [3]. Recent refinements in medical imaging, both-
pre- and intra-operatively, have been of great help to the surgeons. Further assessment of
new technology is in progress, namely of intra-operative isotopic detection of the tumors
using hand-held probes after I1I n-Pentetreotide administration. Additive information has
been also sought for from the use ofbiological markers aiming at predicting the biologi-
cal behavior of the tumor.
Tumor proliferation markers such as proliferating cell nuclear antigen (PCNA) or
quantitative DNA analysis using flow cytometry have been performed by several groups
on endocrine tumors ofthe pancreas [16, 17]. Results ofPCNA studies indicated that the
lower the frequency of cells expressing the antigen within the tumor, the better was the
survival [16]. Similarly, a close statistical correlation has been found between the degree
ofquantitative abnormalities ofprimary tumor DNA content and tumor spread [17]. The
prognostic significance of the CD44 expression in gastrinoma (i.e., restricted tumor
spread, usually to lymph-nodes in CD44-positive tumors) in contrast to the CD44-nega-
tive tumors, which are more prone to be locally invasive and/or metastasize to the liver
[18] has not been confirmed in a group of 10 gastrinoma patients studied by our group
(unpublished observations).
DETERMINANTS OF SURVIVAL IN PATIENTS
WITH ZOLLINGER-ELLISON SYNDROME.
Liver metastases are present in about 25 percent of ZES patients [1, 2, 3, 13].
Although individual patients with long-term survival have been observed in most centers
caring for ZES patients, it is commonly observed that less than half of the ZES patients
with liver metastases survive beyond five years [1, 2, 13, 19, 20] and less than 30 percent
beyond 10 years [20]: the median survival at five years ranges from 17 to 53 percent. In
contradistinction to liver metastases, the presence oflymph-node metastases, although as
prevalent as liver metastases, does not seem to influence survival rate in ZES patients [1,
9, 20, 21].
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It is not clearly established that chemotherapy or other medical therapies increase sur-
vival since no comparisons of randomized treatments against placebo have been per-
formed.
In sporadic ZES cases, the determinants affecting the development ofhepatic metas-
tases clearly appear to be the size and the location ofthe primary tumor [13, 20]. Patients
presenting with hepatic metastases have larger primary tumors than patients without
metastases, while no such relationship exists between primary tumor size and develop-
ment of lymph-nodes metastases [20]. In the NIH series, indeed, in patients harboring
tumor(s) of more than 3 cm diameter, usually located in the pancreas, liver metastases
were noted in 61 percent of the cases [20]. Pancreatic tumors, usually large, are associat-
ed with liver metastases in 52 percent of sporadic cases; seven percent of these patients
have both lymph node and liver involvement [20]. In contrast, duodenal tumors, which
usually are of small size, are associated with liver metastases in only five percent of the
cases, while they are associated with regional lymph node involvement in the same pro-
portion as in case ofpancreatic primary(ies) [20].
These very important findings seem to be in keeping with the anatomical stratifica-
tion proposed by Howard et al. [22], which sharply separates the patients having primary
tumors located on the right of the superior mesenteric artery, within the so-called gastri-
noma triangle, from those patients having pancreatic tumors to the left of the superior
mesenteric artery; in the latter group, liver metastases were much more prevalent (56 per-
cent ofpatients) and the actuarial survival was poor (less than 10 percent at 10 years).
EXPLORATIVE LAPAROTOMY IN PATIENTS
WITHOUT DISTANT METASTASES
An oncological approach in the surgical management oftumors in patients with spo-
radic ZES has been vigorously suggested by several groups [1, 4, 23], and discussed by
others [24].
Most encouraging results supporting such an approach have been suggested recently
by the retrospective analysis of the clinical outcome of 98 ZES patients (including 15
MEN-1-ZES patients without liver metastases at first presentation) who submitted sys-
tematically to explorative laparotomy as compared to 26 patients, including 9 patients
withMEN-1, who fordiverse reasons did notundergo surgery [11].Among the 98 patients
with surgery, a tumor mass was found in 83 and removed without operative mortality.
During follow-up (mean duration: 6.3 years ± 0.4; range: 0.7 to 16.8), liver metastases
developed in only 3.1 percent of the patients who underwent surgery as compared to
23 percent of the patients who did not undergo surgery (p < .003). Disease-specific actu-
arial survival was 100 percent at 15 years in the group in whom surgery was performed.
In contrast, two deaths related to progression of.liver metastases, were noted in the non-
operated group. Although the difference in survival between these two groups of patients
did not reach statistical significance, these findings are of the utmost importance, sug-
gesting a high benefit in terms ofprevention ofhepatic metastases. This approach clearly
deserves further testing by prospective evaluation.
DETERMINANTS OF DISEASE-CURE BY SURGERY
In contrast to sporadic ZES patients, in whom it appears reasonable to attempt tumor
eradication in the absence of non-resectable liver involvement, in patients with MEN-1-
ZES exploratory laparotomy is seldom indicated (other than for symptomatic associated-
endocrine secretion), as the chance of a definite cure by surgery is very low. Parathyroid
surgery is often indicated and should take place before any form ofabdominal surgery.
Indeed, in this clinical setting, anatomical distribution and tumor morphology are
different from sporadic cases, being usually multiple, disseminated throughout the
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duodenopancreatic area, of small size, and perhaps associated with endocrine cell
hyperplasia. Several types of pancreatic endocrine cell proliferation may coexist in
MEN-1 patients. One of the most puzzling situations has been the association of gas-
trin and insulin overproduction within pancreatic tumors as noted in 13 percent of
cases of ZES with MEN-1 in our experience. Figure 1 represents the basic flow chart
adopted at the Bichat-Claude Bernard Hospital for the detection of MEN-1. The oral
calcium tolerance test has been evaluated prospectively in our institution in 28 patients
with normal fasting total plasma calcium to detect primary hyperparathyroidism [25].
Fasting total and ionized calcium and PTH 1-84 levels were measured, and nephroge-
nous cAMP was calculated during a two-hour baseline period and during a two-hour peri-
od after the oral administration of 1 g inorganic calcium. The diagnosis of normocalcemic
primary hyperparathyroidism was established when, during the oral calcium tolerance
test, plasma ionized calcium concentration increased to supranormal values and only a
minimal reduction in plasma PTH concentration and nephrogenous cAMP excretion was
observed. Among the patients with normal fasting total calcium levels, the test established
the diagnosis of normocalcemic primary hyperparathyroidism in five (20 percent) and of
hypercalcemic primary hyperparathyroidism in three patients. In nine percent of the
patients with apparently sporadic type ofthe ZES (no other endocrinopathy and no famil-
ial disease), normocalcemic primary hyperparathyroidism was the sole manifestation of
MEN-1. Thus, in this prospective study, a diagnosis of normocalcemic primary hyper-
parathyroidism was established in four out of 23 ZES patients with normal basal serum
calcium levels [25].
The management strategy in patients with ZIS-MEN-I that has been adopted at the
Bichat Hospital derives from the experience gained with the aggressive surgical approach
that was applied to these patients from 1959 to 1981 [14, 15]. As illustrated in Figure 2,
36 patients underwent some form of gastrinoma surgery. After surgery 22 patients were
judged tumor-free and seven had residual tumor. On subsequent follow-up, only one
remained, apparently cured after 96 months; in all other cases, persisting clinical or bio-
logic abnormalities have been noted, and overt tumor(s) recurrence has been documented.
I
Clinical assessment: Laboratory and Imagery Screening:
- Neuroglycopenia symptoms suggesting associated - Parathyroid function
insulinoma or serum Ca and phosphorus level (3 days)
- Diabetes and skin lesions glucagonomas urinary Ca and phosphorus outputs (3 days)
urinary cyclic AMP output if necessary
serum PTH
- Nephrolithiasis, suggesting primary oral calcium tolerance test ifnecessary
polyuro-polydypsia hyperparathyroidism Pituitary function
serum prolactin levels (3 days)
sella turcica CT scan or MNR
- Family history ofpeptic ulcer disease - Adrenals
or endocrine diseases . serum K
serum free cortisol at 8 am and 6 pm
urinary free cortisol output
- Genetic testing when appropriate adrenal CT scan
Fasting blood glucose
insulin
C-peptide
24-hour fasting ifnecessary
Figure 1. Work-up schedule of patients with Zollinger-Ellison syndrome (ZES for the detec-
tion ofmultiple endocrine neoplasia type I (MEN I) (Bichat-Claude Bernard Hospital).
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Table 1. Main demographic, clinical and evolutive features of 45 cases of ZES-MEN I com-
pared to 127 sporadic ZES followed at Hospital Bichat-Claude Bernard (1959 1989).a
ZES-MEN I Sporadic ZES
(n=45) (n= 127)
Percent patients 26 74
Sex ratio male/female 1.8 2.3
Malignancy percent 47 55
* Liver metastasis 31 30
* Other metastasisb 16 25
Death tollaC
*Total (%) 38 44
*Related to LM(%) 12 36
aMedian follow-up 95 months (17-278); bpredominantly lymph nodes; cdeath toll related to liver
metastases progression tended to be less in ZES-MEN I (p = 0.11).
Furthermore, in seven patients, metachronous liver metastases developed after a median
delay of88.5 months (range six to 108 months). Only two patients in this group had a gas-
trinoma with a diameter larger than 3 cm at surgery. It is worth noting that all but one of
these operated patients were apparently free of tumor after surgical exploration. The lat-
ter findings, rather than the relatively high death rate during the first half of our experi-
ence (1959-1974, i.e., before the advent ofH2RA), reassures us in the interventionist strat-
egy that we adopted.
I cured t 96 months IPeristingbilogicaianomalie (n.17) Overt tumor(s) recurrence (na9)
Figure 2. Experience gained with the surgical management and follow-up of45 patients with
Zollinger-Ellison syndrome (ZES) associated with multiple endocrine neoplasia type I (ZES-
MEN I) at Hospital Bichat. Bichat ZES series 1959-1989: 172 patients.
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Table 2. Comparative clinical characteristics of 185 ZES patients according to their
benign or malignant course.
Clinical course
Benign Malignant
Characteristics Percent patients: 76 Percent patients: 24
Present with liver metastases (%) 0 19
Develop liver metastases (%) 0 5
MEN I (initial evaluation) (%) 21 6 (uncommon)
Time from onset to diagnosis (years) Long (mean 5.9) Shorter 2.7 (mean)
Size ofprimary tumor (%) small < 1 Large > 3
Location ofprimary tumor (%) 66, primarily duodenum 92, primarily pancreatic
Survival at ten years 96, excellent 30, poor
*i.e., no liver metastasis development. N.B. All patients without MEN I and liver metastases under-
went surgery. From Weber et al. [20] with the permission ofthe Editor.
Actuarial survival, at 15 years, in the ZES-MEN-1 patients followed in our institution
was 63 percent, thus slightly better than in sporadic cases (45 percent) [26]. In addition,
when the mortalities for both categories ofZES were compared (Table 1), a trend in favor
ofthe ZES-MEN I group was noticeable in terms ofdeath related to liver metastatic pro-
gression. When deaths unrelated to liver metastases were excluded from our evaluation,
survival rate after a median follow-up of95 months (range: 17 to 278) for the whole pop-
ulation was 78 percent, a figure close to the one reported by Weber et al. [20]. It is possi-
ble, as suggested by the prospective long-term study ofthe large group ofpatients studied
at the NIH by Weber et al. [20], that there are two forns ofZES with strikingly different
clinical outcomes. A comparison of the main clinical characteristics of these two groups
ofpatients is illustrated in Table 2.
Will such a posteriori stratification and its consequent ZES management-guidelines
benefit the patients not only with regard to survival but also for disease cure? According
to results reviewed by Fraker and Norton [23], and our own experience up to 1985 [1], the
chance of a definite cure by tumor removal in those patients without distant metastases
and without MEN-I approximated 18 to 20 percent in patients with pancreatic gastrino-
mas, and up to 40 to 65 percent in those patients with extra-pancreatic gastrinomas (i.e.,
tumors located in the duodenal or the gastric wall, isolated lymph node metastasis) [1].
Altogether in the NIH experience, however, the cure rate at five years appears to be about
30 percent, although this rate amounted to 58 percent at three months [27]. In the group
Table 3. Requirements for efficacious surgical tumor eradication in ZES patients: Present
Hospital Bichat-Claude Bernard strategy.
* MEN I exclusion:
- Thorough iterative endocrinological assessment
- Oral calcium tolerance test (Iary HPT early diagnosis)
* Liver, bone and other site metastases exclusion (surgery contraindications)
* Precise tumor(s) localization
- Conventional imagery (MNR and CTS)
- Upper digestive endoscopy
- EUS (for pancreas, duodenum and peripancreatic lymph nodes)
- SRS: preoperative (interest for patient management)
MNR, magnetic nuclear resonance; CTS, computerized tomography scan;
EUS, endoscopic ultrasonography; SRS, somatostatin-receptors scintigraphy.
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Table 4. Results of endoscopic ultrasonography (EUS), upper gastrointestinal endoscopy
(UGI), computerized tomography (CTscan), for diagnosis ofduodenal, pancreatic and lymph
node gastrinomas in 22 ZES patients followed at Hospitals Beaujon (Clichy), Bichat-Claude
Bernard (Paris) and Reims.
True True False False Sensitivity Specificity
+ + (%) (%)
Duodenal wall tumors
EUS 5 12 0 5 50 100
UGI endoscopy 4b 12c 0 6 40 100
CT scan 0 12 0 10 0
Pancreatic tumors
EUS 3 18 0 1 75 100
CT scan 1 18 0 3 25 100
Lymph node tumors
EUS 5 12 2 3 62.5 86
CT scan 0 14 0 8 0 100
aTp.wo were not seen by upper gastrointestinal endoscopy; bone was not seen by EUS; cincludes biop-
sy-negative nodules ofduodenal mucosa, 2 to 4 mm in diameter in two patients. From Ruszniewski
et al. [30].
of42 patients, however, who were found to be disease-free after surgery as defined by no
evidence of tumor on imaging studies, normal fasting gastrin level, and negative provoca-
tive test, the proportion of disease-free patients amounted to 62 percent at five years and
a little less than 50 percent at nine years [27].
It is essential to emphasize that comparison of the survival curves in patients who
underwent surgical exploration for possible complete tumor resection at the NIH [10, 20]
showed no significant difference whether the patients were rendered disease-free or not.
PRESENT STRATEGY FOR ZES MANAGEMENT AT THE
BICHAT-CLAUDE BERNARD INSTITUTION
The policy that has been presently adopted at the Bichat-Claude Bernard Hospital
has been outlined in Table 3. It emphasizes the necessity before considering surgery in
ZES patients: 1) to exclude the presence of MEN-1; 2) to eliminate the presence of dis-
tant metastatic spread; and 3) to make the strongest efforts at precise localization of the
primary tumor(s). Modern medical imaging (i.e., endoscopic ultrasonography and
somatostatin-receptor scintigraphy using IIlIn-Pentetreotide) are of the greatest help as
illustrated in Tables 4 and 5 [29, 30, 311. As shown in Tables 5 and 6, somatostatin-recep-
Table 5. Interest ofsomatostatin scintigraphy in ZES patients. Results ofprospective studies by
NIH [31] and Hospital Bichat-Claude Bernard (1993 to 1995) [32, 33].
NIH 1995* Bichat 1995
(n=46) (n=21**,n=68***)
In-tumor localization SE (percent)
- Duodeno-pancreatic tumors* s4t 58
- Hepatic tumors 100 100
Patient management (percent)** 47 41
From: *Gibnl et al. [31]: tcalculation from available data in the abstract; **Cadiot et al. [32];
***Bonnaud et al. [33].
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Table 6. French experience with liver transplantation for metastases for neuroendocrine
tumors (1989-1994) [43].
Actuarial survivala One year Two years Five years
Carcinoids (n = 14) 78% 78% 78%
Other NET (n = 14) 28% 9%
tor scintigraphy is slightly less sensitive than ultrasonography in detection ofprimaries in
the duodeno-pancreatic area. However both techniques are, in our experience, comple-
mentary since each one can reveal tumor masses undetected by the other [29, 32].
Concerning the detection ofextrapancreatic gastrinoma, for instance, the combination of
ultrasonography and somatostatin-receptor scintigraphy yielded positive results in 90 per-
cent of our patients [32]. In addition to tumor localization, somatostatin-receptor scintig-
raphy has been evaluated at both the NIH and our institution in terms ofpatient manage-
ment guidance, as shown in Table 5. More than 40 percent ofthe patients benefited from
this major technological addition. From our experience, now including 78 patients with
proven gastrinomas, somatostatin-receptor scintigraphy should be included in primary
investigation ofpatients with biological diagnosis ofgastrinoma and in selecting patients
eligible for a curative surgery.
ROLE OF MEDICAL MANAGEMENT IN PATIENTS
WITH SECONDARY MALIGNANCY
Various therapeutic tools for liver metastases have been proposed, since surgery is
rarely curative, except in some selected cases and in very specialized surgical centers [3,
34]. The experience of two surgical groups indicates that extensive resection including
major hepatic resection is feasible, safe and can be repeated. Clinical outcome after hepat-
ic resection, compared to the natural history of these tumors, demonstrates that this pro-
cedure is valuable in terms ofsymptoms palliation and prolongation ofsurvival, provided
athorough selection ofcandidates forsurgery and asignificant resection oftumordeposits
can be performed [34]. Partial hepatic resection can be combined with tumordebulking to
facilitate the synergistic effect ofvarious other forms oftreatment such as chemotherapy,
serial arterial embolization or repeated transient hepatic ischemia.
Vascular occlusive therapy of pancreatic endocrine tumors metastatic to the liver has
been updated and discussed recently by Arcenas et al. [35]. Although it is beneficial in
patients with liver metastasis originating from gut carcinoid tumors, efficacy in gastrino-
ma patients has not yet been sufficiently evaluated [35, 36].
Considerable hope had been placed on systemic chemotherapy. Early experience with
regimens using a combination ofstreptozotocin (STZ) and 5 fluoro-uracil (5FU) yielded
the best response rates [37]. The median remission duration in the whole group ofpatients
was only 17 months, but there was a trend toward longer survival (26 months) in the STZ-
5FU group versus those receiving STZ alone (16.5 months). Valid interpretation of these
results, however, remained uncertain in ZES because ofthe small number ofZES patients
concerned (eight out of 84 endocrine pancreatic tumors) and becausejudgement criteria
were essentially biological. Recent prospective studies [19, 38] included 21 and 25 ZES
patients, respectively, and measured the response to therapy using both tumor-size regres-
sion and survival times. In ourtrial, STZ-5FU gavedisappointing results including 1) only
one case in which there was a major and long-lasting tumor size regression (greater than
50 percent with 55 months duration); 2), only three cases in which a minor, transient
response was observed (25 to 50 percent tumor-size regression on CT scans); 3) stabi-
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lization of tumor masses in 28 percent of cases; and 4) progression of liver masses in 68
percent of the patients [19]. Actuarial analysis revealed a median survival time of 28
months, 34 percent ofpatients were alive at five years [19].
Moertel and colleagues [38] compared STZ-5FU to chlorozotocin and to doxorubicin
with STZ in various types ofmetastasized endocrine tumors. Although the combination of
STZ and doxorubicin was the most effective, it still provided a relatively small chance of
complete tumor-size regression (18 percent) and oflong-term survival (around 30 percent
ofpatients were alive at five years).
Treatment with the long-acting somatostatin analog, octreotide acetate, offers the the-
oretical advantage because it acts by inhibiting gastrin release together with gastric acid
secretion and by antagonizing tumor growth. However, clinical use ofoctreotide is ham-
pered by the easier use of potent antisecretory drugs while its effects on tumor size
appears to depend upon the developmental stage of the tumor [39] and to be modest and
inconstant [39, 40].
The advent of liver transplantation raises a challenging therapeutic option for liver
metastases from endocrine gut tumors that are recognized as having aslow evolution [41].
Makowka et al. from Starzl's group [42] reported results from five such patients (one with
gastrinoma). Their results appeared encouraging for two glucagonoma patients who
remained disease-free 23 and 41 months later. The only gastrinoma patient, who was ini-
tially free ofextrahepatic metastases, diedeightmonths later from multiple lung and bone
metastases.
A large French experience with liver transplantation for neuro-endocrine liver metas-
tasis extending from 1989 to 1994 has been recently analyzed and published in an abstract
form [43]: the main results are shown in Table 6. As can be noted, with the exception of
gut carcinoids, results of liver transplantation are not encouraging for the pancreatic
endocrine tumors inclusive ofgastrinomas. In addition, a real problem for such a tremen-
dous decision is when to perform liver transplantation? In a study of 35 patients with
endocrine-type liver metastases including 20 cases ofZES, we looked for factors specific
to endocrine-type liver metastases that could be used as major prognostic indicators of
death and, thus, could be ofhelp in selecting the appropriate time for liver transplantation
[44]. Among the various elements assessed over a patient's observation period of 35
months (median duration; range: five to 136 months), only rapid expansion of metastatic
volume of the liver (more than 25 percent within six months) seemed to be a major prog-
nostic factor leading to consideration of liver transplantation in patients below 55 to 60
years without bone and lung metastases and non-responding to other forms of therapy.
There is insufficient experience with interferon in gastrinoma patients with liver
metastases; interesting results obtained in carcinoid tumors suggest interferon could be
worth testing in ZES patients, possibly in association with octreotide [45].
CONCLUSIONS
The role of medical treatment is essential in gastrinoma management for a large
group ofpatients since:
1. Unresectable hepatic metastases are present in about 25 percent ofpatients with
ZES.
2. Surgery is usually unable to achieve disease-cure inMEN-i-ZES cases (25 percent
ofpatients with ZES).
3. Recurrence rate is 50 percent at nine years without affecting survival, even in
benign forms ofsporadic ZES, according to the NIH stratification.
Results ofthe long-term study at the NIH suggest, however, that in sporadic forms of
the disease, surgery could play a major role to prevent liver metastasis development; this
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suggestion, however, requires further testing. Surgery, in any case, must be safe, per-
formed by experienced surgical-medical teams. and restricted to simple procedures.
The time has probably come to initiate multicenter, multinational studies to test:
1. The NIH-proposed stratification between benign and malignant forms of ZES
through retrospective and prospective, randomized clinical experiences.
2. The role of surgery in MEN-1-ZES patients.
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